China NMPA Drug Inspection - Zhengzhou Ruilong Pharmaceutical Co., Ltd. - Purple gromwell

China NMPA drug inspection for Zhengzhou Ruilong Pharmaceutical Co., Ltd. published August 29, 2022. Drug: Purple gromwell. In August 2022, the National Medical Products Administration (NMPA) issued Announcement No. 39, identifying 20 batches o

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Zhengzhou Ruilong Pharmaceutical Co., Ltd.

Inspection Date

Unknown Date

Product Type

ID: ada860cc-413e-48cf-8566-e7fe37cc5bd9

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox